107 related articles for article (PubMed ID: 17952745)
1. Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.
Abrunhosa-Branquinho AN; Bar-Deroma R; Collette S; Clementel E; Liu Y; Hurkmans CW; Feuvret L; Van Beek K; van den Bent M; Baumert BG; Weber DC
Radiother Oncol; 2018 May; 127(2):292-298. PubMed ID: 29606522
[TBL] [Abstract][Full Text] [Related]
2. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.
Wick W; Roth P; Hartmann C; Hau P; Nakamura M; Stockhammer F; Sabel MC; Wick A; Koeppen S; Ketter R; Vajkoczy P; Eyupoglu I; Kalff R; Pietsch T; Happold C; Galldiks N; Schmidt-Graf F; Bamberg M; Reifenberger G; Platten M; von Deimling A; Meisner C; Wiestler B; Weller M;
Neuro Oncol; 2016 Nov; 18(11):1529-1537. PubMed ID: 27370396
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
van den Bent MJ; Tesileanu CMS; Wick W; Sanson M; Brandes AA; Clement PM; Erridge S; Vogelbaum MA; Nowak AK; Baurain JF; Mason WP; Wheeler H; Chinot OL; Gill S; Griffin M; Rogers L; Taal W; Rudà R; Weller M; McBain C; Reijneveld J; Enting RH; Caparrotti F; Lesimple T; Clenton S; Gijtenbeek A; Lim E; Herrlinger U; Hau P; Dhermain F; de Heer I; Aldape K; Jenkins RB; Dubbink HJ; Kros JM; Wesseling P; Nuyens S; Golfinopoulos V; Gorlia T; French P; Baumert BG
Lancet Oncol; 2021 Jun; 22(6):813-823. PubMed ID: 34000245
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.
Koukourakis GV; Kouloulias V; Zacharias G; Papadimitriou C; Pantelakos P; Maravelis G; Fotineas A; Beli I; Chaldeopoulos D; Kouvaris J
Molecules; 2009 Apr; 14(4):1561-77. PubMed ID: 19384285
[TBL] [Abstract][Full Text] [Related]
5. MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas.
Zhao B; Qi H; Ma W
JAMA Oncol; 2023 Dec; 9(12):1734-1735. PubMed ID: 37856142
[No Abstract] [Full Text] [Related]
6. MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas-Reply.
Kinslow CJ; Cheng SK; Wang TJC
JAMA Oncol; 2023 Dec; 9(12):1735-1736. PubMed ID: 37856114
[No Abstract] [Full Text] [Related]
7. Radiotherapy of High-Grade Gliomas: First Half of 2021 Update with Special Reference to Radiosensitization Studies.
Frosina G
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445646
[TBL] [Abstract][Full Text] [Related]
8. Effect of Temozolomide Combined with Intensity Modulated Radiation Therapy on Serum Factor, Immune Function and Clinical Efficacy in Postoperative Glioma Patients.
Yuan J; Liu J; Fan R; Liu Z
Radiat Res; 2023 Sep; 200(3):289-295. PubMed ID: 37797165
[TBL] [Abstract][Full Text] [Related]
9. Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.
Jo J; Williams B; Smolkin M; Wintermark M; Shaffrey ME; Lopes MB; Schiff D
J Neurooncol; 2014 Oct; 120(1):155-61. PubMed ID: 25038848
[TBL] [Abstract][Full Text] [Related]
10. An NF-κB p65-cIAP2 link is necessary for mediating resistance to TNF-α induced cell death in gliomas.
Zhao X; Laver T; Hong SW; Twitty GB; Devos A; Devos M; Benveniste EN; Nozell SE
J Neurooncol; 2011 May; 102(3):367-81. PubMed ID: 21279667
[TBL] [Abstract][Full Text] [Related]
11. Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy.
McCann CM; Waterman P; Figueiredo JL; Aikawa E; Weissleder R; Chen JW
Neuroimage; 2009 Apr; 45(2):360-9. PubMed ID: 19154791
[TBL] [Abstract][Full Text] [Related]
12. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
13. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathological diagnosis of gliomas by genotype analysis].
Nakamura M; Shimada K; Nakase H; Konishi N
Brain Nerve; 2009 Jul; 61(7):773-80. PubMed ID: 19618854
[TBL] [Abstract][Full Text] [Related]
15. [Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].
Molnár P; Méhes G
Magy Onkol; 2009 Mar; 53(1):33-8. PubMed ID: 19318324
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Schiff D
Cancer Invest; 2007 Dec; 25(8):776-84. PubMed ID: 17952745
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
